Mission
AMPEL BioSolutions was founded to bring personalized precision medicine to patients, especially those with autoimmune and inflammatory diseases.
Our Why
Autoimmune and inflammatory disease patients are not receiving the precise, personalized evaluation and treatment that they deserve. The immune system of autoimmune patients is complex, dynamic and not accurately assessed by current technologies.
The AMPEL team brings their expertise in basic and translational research, clinical trial design, and bioinformatics together in a new way to develop scalable systems using AI and deep machine learning to improve patient outcomes. To give patients and their doctors the tools and information necessary to make decisions based on that individual’s genomic profile — what we term their Genomic Fingerprint.
AMPEL’s first product, the, LuGENE® LDT blood test is now launching at several Lupus practices around the country including those in medical centers, concierge practices and healthcare systems as a practical decision support biomarker test that could greatly impact day-to-day healthcare for patients with Lupus. LuGENE® predicts flares before they happen and provides specific information about a patient’s disease abnormalities leading to symptoms, allowing physicians to make evidence-based decisions regarding therapy including whether a patient is stable on their current therapeutic regimen. AMPEL’s technology covers >95% of all known genes and is disease agnostic so there is capacity to expand reporting of results into new disease indications without developing a new test. AMPEL’s exclusive curated database of >20,000+ autoimmune patient gene expression profiles and 5,000+ healthy individuals with rich clinical information is the world’s largest and fuels machine learning predictions based on evidence.
Expertise
RNA analytics, Bioinformatics and Machine Learning/AI
Disease Areas
Systemic Lupus Erythematosus, Psoriasis, Scleroderma, Atopic Dermatitis, Lupus Nephritis, Fibromyalgia, Cardiovascular, Sjogren’s Syndrome, Lung Cancer, SARS-Cov2
Why AMPEL
Reproducible
Blood or Biopsy tests for providers
Scalable
From Pharma to mainstream adoption by providers
Translatable
Digital Health Tool
Clinical Decision Support
Precise real-time evaluation of immune status
Clinical Care Pathway
Evidence-based disease management through RNA analytics
Who We Work With
AMPEL seeks relationships with Pharmaceutical and Precision medicine companies:
• Co-Develop RNA analytic tests in desired disease areas
• License with field of use for specific conditions
• Use of AGP®, Bioinformatic tools and ML/AI Algorithms
Company Milestones
Patents
AMPEL’s technology is covered by 15* patents filed & pending by WSGR/Greenberg Traurig in Immunology, inflammation, Infectious disease and oncology.
Database
Exclusive curated database of >25,000 Autoimmune and normal individual gene expression profiles with rich clinical information.
World’s Largest for Lupus.
Validation and Expansion
Approach validated by KOLs and 20+ pharma/biotech clients.
Reimbursement for 1st Product LuGENE expected H2 2026.
Launch and Growth
2025 Planned Activities
- LuGENE® Clinical Care Launch
- DermaGENE® – Psoriasis CLIA Certification
- WellGENETM – Validation
Peer-Reviewed Articles
Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications
Molecular mechanisms governing the progression of nephritis in lupus prone mice and human lupus patients
Altered expression of genes controlling metabolism characterizes the tissue response to immune injury in lupus
The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus
Deconvoluting the heterogeneity of SLE: The contribution of ancestry
Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries
Molecular pathways identified from single nucleotide polymorphisms demonstrate mechanistic differences in systemic lupus erythematosus patients of Asian and European ancestry
COVID-19 Patients Exhibit Unique Transcriptional Signatures Indicative of Disease Severity
Transcriptomics data: pointing the way to subclassification and personalized medicine in systemic lupus erythematosus
Molecular endotypes of type 1 and type 2 SLE
Medelian Randomization and Pathway Analysis Demonstrate Shared Genetic Associations Between Systemic Lupus Erythematosus and Coronary Artery Disease
